High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM

The Company Also Reports Positive Free Cash Flow and Net IncomeThe Company's German Medical Cannabis Subsidiary, Remexian Pharma GmbH (Remexian) Generated Record Revenue of $31.6 Million with Gross Margins Increasing to 27%The Company Has Secured Credit Approval with…

Read the full release →

News provided by PR Newswire.